Skip to content
DataLookout
Menu

NCT05788107

Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HLX51 in Patients With Solid Tumor or Lymphoma

StatusUnknown
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 2 versions: 2 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Mar 2023); last known: Not Yet Recruiting
  2. Notable Primary completion date: May 2024 to May 2025
    • Start date: Jun 2023 to Jun 2024
    • Study completion date: Oct 2024 to Oct 2026
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

The Dose-Limiting Toxicity (DLT) of HLX51 within 3 weeks after the first Administration
Timeframe: At the end of Cycle 1 (each cycle is 21 days)
The maximum tolerated dose (MTD) of HLX51 within 3 weeks after the first administration
Timeframe: At the end of Cycle 1 (each cycle is 21 days)

Arms and interventions

HLX51 GroupExperimental

The initial dose of HLX51 is 0.3mg/kg, and 5 dose levels are designed: 0.3 mg/kg, 1 mg/kg , 2.5mg/kg, 5mg/kg, and 10mg/kg (Q3W). Patients with good tolerability and well controlled disease will receive the treatment until progressive disease (PD) without any clinical benefit, initiation of other anti-tumor therapies, death, intolerable toxicity, or withdraw the informed consent (whichever occurs first).

Drugs: HLX51